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Abstract
Changes in body fat distribution in virologically suppressed HIV-infected patients switching from lopinavir/
ritonavir (LPV/r) to atazanavir/ritonavir (ATV/r) were assessed. A prospective comparative study was con-
ducted of 37 patients receiving LPV/r regimens switching to ATV/r with 46 patients continuing with LPV/r.
Body composition was assessed with whole-body dual-energy x-ray absorptiometry (DXA). Abdominal CT
scans were also performed in a subset of patients. Groups were comparable in baseline demographic, clinical,
and anthropometric characteristics. After 12 months, peripheral fat did not change significantly, but an increase
in trunk fat was observed only in the ATV/r group (0.87 kg, p¼ 0.021). The percentage of patients with an
increase 20% in total fat was 37.8% and 15.2% in the ATV/r and LPV/r groups, respectively ( p¼ 0.018). In the
ATV/r group, the increase in trunk fat (9.4%) was significantly higher than in peripheral fat (3.7%) ( p¼ 0.007),
leading to a significant increase in fat mass ratio (3.76%, p¼ 0.028), whereas no significant differences were found
among LPV/r patients. CT scans showed that abdominal fat increase corresponded to both visceral (28%,
p¼ 0.008) and subcutaneous fat (42%, p¼ 0.008). These data suggest that switching from LPV/r to ATV/r is
associated with increased trunk fat, both subcutaneous and visceral.
Introduction
Highly active antiretroviral therapy (HAART)plays a central role in the development of lipodystrophy
syndrome. Changes in body composition can cause signifi-
cant psychological morbidity and compromise adherence to
therapy. Moreover, metabolic alterations that are commonly
associated can increase the risk of cardiovascular diseases in
the long term.1
While thymidine analogues have been strongly implicated
in peripheral fat loss, lipoatrophy,2 the factors involved in
the pathogenesis of central fat accumulation are less clearly
defined.
Lipodystrophy is a multifactorial syndrome and the exact
cause remains elusive. Protease inhibitor (PI) therapy, how-
ever, has been implicated in its etiology. To varying degrees,
the majority of PIs have been associated with the metabolic
disturbances and/ormorphological alterations that constitute
the lipodystrophy syndrome.3,4 Atazanavir (ATV), unboosted
or boosted with ritonavir (ATV/r), seems less likely to cause
dyslipidemia and other adverse metabolic effects compared
with other PIs.5–9 These findings have been observed both in
naive and in pretreated patients.5–10 Several studies switching
from other PIs, including lopinavir/ritonavir (LPV/r) to
ATV/r, have been previously conducted with the aim of
simplifying therapy and improving tolerability and the lipid
profile.6,8,9 However, little information is available comparing
body fat changes between patients receiving different PIs, and
specifically, the effect of switching from LPV/r to ATV/r on
changes in body composition remains unclear.11,12
The objective of this study was to compare the impact on
body fat distribution of switching from LPV/r to ATV/r in
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otherwise healthy virologically suppressed HIV-infected pa-
tients. Although a few studies conducted in different scenar-
ios and comparing these two drugs in terms of changes in fat
distribution have been presented, this is the first study to be
published showing that ATV/r is associated with a greater
increase in trunk fat and therefore it adds valuable data to the
scant information available in the literature.12–14
Materials and Methods
This was a 12-month, prospective, open-label, comparative
multicenter study of HIV-1-infected patients aged at least 18
years who switched from LPV/r to ATV/r or continued with
the same therapy. Patients were recruited under conditions of
daily practice at the HIV Units of five acute-care university-
Table 1. Baseline Demographic, Clinical, Anthropometric, and DXA Data
Treatment group
Variable ATV/r (n¼ 37) LPV/r (n¼ 46) p-value
Age, years 42.4 (28.3, 73.7) 41.7 (30.2, 63.5) 0.527
Male sex, n (%) 29 (78.4) 35 (76.1) 0.805
HIV transmission group, n (%)
Injection drug user 12 (32.4) 9 (19.6) 0.203
Male homosexuality 6 (16.2) 16 (34.8)
Heterosexual transmission 18 (48.6) 19 (41.3)
Other 1 (2.7) 2 (4.3)
AIDS, n (%) 13 (35.1) 26 (56.5) 0.052
CDAþ, cells/ml 425.3 (108, 1239.5) 438 (153, 945) 0.836
HIV-1 RNA, copies /ml 99 (19, 323) 69.5 (19, 283) 0.154
Concurrent NRTI therapy, n (%)
Tenofovir 28 (75.7) 28 (60.9) 0.152
Lamivudine 12 (32.4) 25 (54.3) 0.046
Didanosine 13 (35.1) 7 (15.2) 0.035
Zidovudine 3 (8.1) 13 (28.3) 0.021
Abacavir 7 (18.9) 6 (13.0) 0.550
Stavudine 5 (13.5) 7 (15.2) 0.826
Emtricitabine 4 (10.8) 0 0.036
Concurrent NNRTI therapy, n (%)
Nevirapine 0 2 (4.3) 0.500
Efavirenz 0 0
Other protease inhibitors, n (%)
Saquinavir 1 (2.7) 0 0.446
Lipid lowering drugs, n (%) 4 (10.8) 12 (26.1) 0.079
Hypoglycemic drugs, n (%) 2 (5.4) 2 (4.4) 1.000
Lipid profile
Cholesterol, mmol/liter 5.1 (3.7, 7.5) 5.6 (2.4, 8.4) 0.238
LDL-c, mmol/liter 3.0 (1.5, 5.6) 3.2 (1.2, 5) 0.992
HDL-c, mmol/liter 1.2 (0.7, 2.3) 1.3 (0.5, 2) 0.892
VLDL-c, mmol/liter 0.4 (2.9, 265.6) 1 (0.3, 3.4) 0.235
Triglycerides, mmol/liter 1.8 (0.8, 10.3) 2.2 (0.5, 11.8) 0.204
Glucose, mmol/liter 4.9 (2.8, 6.6) 5 (3.8, 49.3) 0.205
Insulin, mmol/liter 55.8 (14.3, 223) 61 (14.3, 397) 0.691
Peptide C, mmol/liter 731.5 (301, 1708) 827.5 (210, 2576) 0.149
HOMA 1.7 (0.4, 9.1) 2 (0.4, 17.7) 0.370
Anthropometric characteristics
Weight, kg 66.5 (42.6, 104.3) 68.5 (41, 108.7) 0.339
Body mass index, kg/m2 22.2 (16.6, 43.4) 24.6 (16.6, 39.4) 0.073
Waist circumference, cm 82 (55, 107) 87 (66, 118.2) 0.100
Waist-to-hip ratio 0.9 (0.6, 1.1) 0.9 (0.8, 1.1) 0.262
DXA data
Trunk fat, kg 7.65 (1.89, 30.81) 8.66 (1.44, 25.5) 0.401
% Trunk fat 24.41 (6.55, 56.55) 27.33 (5.51, 55.02) 0.500
Peripheral fat, kg 4.69 (1.30, 21.29) 4.97 (0.95, 25.66) 0.886
% Peripheral fat 19.04 (5.73, 53.86) 18.81 (4.05, 55.36) 0.900
Fat mass ratio 1.14 (0.57, 2.27) 1.34 (0.68, 4.06) 0.103
Total fat, kg 13.90 (3.44, 52.09) 13.79 (2.94, 51.17) 0.571
% Total fat 23.01 (6.90, 55.42) 23.53 (6.09, 53.10) 0.704
Data as median (range) unless otherwise stated.
DXA, duel-energy x-ray absorptiometry; ATV/r, atazanavir/ritonavir; LPV/r, lopinavir/ritonavir; NRTI, nucleoside reverse transcriptase
inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very
low-density lipoprotein; HOMA, homeostatic model assessment.





















































affiliated hospitals in Barcelona, Spain, with extensive ex-
perience in HIV management. Virologically suppressed
HIV-infected patients who were stable on LPV/r-based regi-
mens were eligible. The study was approved by the Ethics
Committee at each center, and all patients gave written in-
formed consent.
An elective switch from LPV/r (400/100mg twice a day) to
ATV/r (300/100mg every day) was offered to 37 consecutive
HIV-positive subjects aged 18 years with undetectable viral
load (HIV-1 RNA levels <100 copies/ml) for reasons of
therapy simplification, lipid disturbances, or other. Subse-
quently, another group of 46 patients receiving an LPV/
r-based regimen, adjusted by age, sex, and weight, was
consecutively offered to serve as controls.
Changes in body fat distribution assessed by dual-energy
x-ray absorptiometry (DXA) scans were the primary outcome
measure. Body compositionwas assessed at baseline and at 12
months. Whole-body DXA scans were performed using a
Lunar DPX-L densitometer (Lunar Radiation Corporation,
Madison, WI). Peripheral limb fat was the sum of arm and leg
fat mass. Trunk, peripheral, and total fat (absolute and per-
centage changes) as well as the proportion of patients with
20% fat changes and fat mass ratio (defined according to
Bonnet et al.15) were evaluated. Clinical variables [demo-
graphics, risk transmission group, the clinical stage of HIV
infection or AIDS, concurrent nucleoside analogue reverse
transcriptase inhibitors (NRTIs) and nonnucleoside reverse
transcriptase inhibitors (NNRTIs), use of lipid-lowering
drugs, and use of hypoglycemic drugs], anthropometric data
[weight, height, body mass index (BMI), waist, waist-to-hip
ratio], and laboratory tests [CD4þ T cell lymphocytes, HIV-1
RNA levels, total serum cholesterol, triglycerides, very-
low-density lipoprotein (VLDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL)
cholesterol, glucose, insulin, C-peptide, and insulin resistance
(HOMA)] were obtained fasting and measured at baseline
and at 12 months. Abdominal computed tomography (CT)
scans were also performed in a subset of patients.
Between-group differences were analyzed with the Stu-
dent’s t test or the Mann–Whitney U test and within group
differences with the paired t test or the Wilcoxon signed-rank
test for normally and not normally distributed data, respec-
tively. Categorical variables were compared with the chi-
square (w2) test. Correlation between DXA and CT results was
assessed using the Pearson’s correlation coefficient. Multi-
variate logistic regression analysis was used to estimate the
best predictors of total fat increase 20%. Statistical signifi-
cance was set at p< 0.05. Statistical analyses were conducted
with SPSS, version 15.0 (Chicago, IL).
Results
A total of 83 virologically suppressed HIV-1-infected pa-
tients were evaluable; of these 37 switched from LPV/r to
ATV/r and 46 continued on LPV/r-based regimens and were
chosen as controls. Baseline clinical, laboratory, andDXAdata
in both study groups were comparable, except for the use of
several nucleoside analogues (Table 1). The median trunk fat
was 8.21 kg (range 1.44, 30.81) and the peripheral fat 4.87 kg
(range 0.95, 25.66).
Regarding lipid changes at 12 months, significant differ-
ences between arms were observed only in triglycerides
(24% ATV/r vs. 1.43% LPV/r, p¼ 0.004) and in VLDL
(24% in ATV/r and 1.08% in LPV/r, p¼ 0.04).
As shown in Table 2, after 12 months as compared with
baseline, there was a statistically significant increase in me-
dian trunk fat [0.87 kg (range 6.9, 8.2), p¼ 0.021] and in
median fat mass ratio [3.76% (range 19.3, 52.7), p¼ 0.028] in
ATV/r patients, whereas these changes in the LPV/r group
were not statistically significant. Changes in peripheral fat
were not significant in any of the two groups. The increase in
total fat almost reached statistical significance in the ATV/r
group only (Table 2). As shown in Fig. 1, in the ATV/r group,
the increase in trunk fat was significantly higher than the in-
crease in peripheral fat [9.4% (range 53.2, 167.3) vs. 3.7%
(range49.9, 122.1), p¼ 0.007]. In the LPV/r group, trunk and
peripheral fat increases were not significantly different [4.3%
(range 54.8, 89.6) vs. 2.5% (range 42.7, 83.1), p¼ 0.223].
No differences were found between groups in the percent-
age of patients with a decrease20% in peripheral fat or in the
percentage of patients with an increase 20% in trunk fat, al-
though the percentage of patients with an increase in total fat
20% was 37.8% in the ATV/r group and 15.2% in the LPV/r
group ( p¼ 0.018). Increases in trunk fat20%were associated
with significant weight and BMI increases in both ATV/r and
LPV/r groups as well as with waist and waist-to-hip increases
in the ATV/r group ( p< 0.05 for all comparisons). However,
increases in trunk fat 20% were not associated with signifi-
cant changes in the lipid parameters in ATV/r patients.
Abdominal CT scanswere available for 21 patients (ATV/r,
n¼ 13; LPV/r, n¼ 8). Body fat changes in trunk fat at 12
months as compared with baseline detected by CT and DXA
correlated significantly (abdominal fat, r¼ 0.914, p< 0.001;
subcutaneous fat, r¼ 0.683, p< 0.001; visceral fat, r¼ 0.843,
p< 0.001). Moreover, in eight patients with trunk fat increases
20% in whom CT scans were performed, significant in-
creases ( p¼ 0.008) in abdominal fat (32.7%), visceral fat
(27.5%), and subcutaneous fat (42.3%) were observed.
In the logistic regression analysis, after excluding BMI and
weight, ATV/r was associated with a total fat increase 20%
(OR¼ 3.39, 95% CI 1.19, 9.62). No differences were observed
in trunk or total fat increase according to the use of thymidine
analogues (data not shown). Also, no relationship was found
between trunk or total fat increase and lipid or glucose
changes at 12 months (data not shown).
Discussion
This prospective study suggests that in patients with vi-
rological suppression, a switch from LPV/r to ATV/r in-
creased trunk fat as shown by DXA, and that this increase
occurred at the expense of both subcutaneous and visceral fat,
according to CT data. In addition, simple anthropometric
measurements, such asweight, BMI, andwaist circumference,
correlated well with DXA findings.
Interestingly, in three other studies, two performed in an-
tiretroviral-naive adult patients and one in stable pretreated
patients, ATV/r use was also associated with an increase in
abdominal fat and/or an increase in trunk-to-limb ratio.12–14
In a substudy of the CASTLE study, which compared ATV/r
with LPV/r in 224 patients, the subgroup of patients with low
BMI presented a significant increase in both visceral and
subcutaneous abdominal fat as measured by DXA, compared
with LPV/r patients, as well as a significant increase in the





















































change of the trunk-to-limb fat ratio at week 96.13 In the
BASIC study, comparing ATV/r with SQV/r in 120 patients,
again ATV/r use was associated with a significant increase in
visceral fat, and in this case, also with an increase in limb fat.14
In the REAL study, performed in 201 virologically suppressed
patients randomly assigned to continue with LPV/r or to
switch to ATV/r, a significant increase in trunk-to-limb ratio
was observed only in ATV/r patients (2.6% increase in trunk
fat, 0.9% in limb fat, difference p¼ 0.02) after 48 weeks.12
Conversely, in a small randomized study enrolling only 15
patients (8 vs. 7), the switch from LPV/r to ATV/r was as-
sociated with a reduction in visceral fat and an increase in
glucose uptake by muscle.16
Although ATV/r patients had a significant improvement
compared to LPV/r patients in some lipid parameters, as
observed in other studies,6,7 we did not find any correlation
between metabolic changes and fat increase. Thus, the
mechanism of this possible association between ATV/r and
abdominal fat increase as well as its clinical relevance remain
unclear.
One of the main obstacles for good management of lipo-
dystrophy is a lack of a standard definition of this for HIV-
associated complications. It has been suggested that fat mass
ratio (FMR) may help in diagnosing lipodystrophy.15,17–19 In
this study, FMR significantly increased in the ATV/r arm
due to a greater increase in abdominal fat than in peripheral
fat. The value of prospectively assessing fat mass ratio
changes in patients receiving antiretroviral therapy to pre-
vent the development or progression of abnormal fat redis-
tribution is unknown at present but should be studied
further.
Our data should be interpreted with caution due to the
limitations of the study, in particular the nonrandomized
design, the relative small number of patients, and the fact that
CT scans were available for only less than half of the study
patients. However, groups were well balanced in most base-
line characteristics, and no correlation was found between
the use of thymidine analogues—the only relevant base-
line characteristic not well balanced between both groups of
patients—and fat increase. In addition, despite the small
sample size, several statistically significant findings were
observed both with DXA and CT scan assessment.
Finally, our results suggest that an ATV/r-based regimen
as a simplification strategy does not have a favorable impact
on body fat redistribution in treatment-experienced HIV-
infected patients when compared with those maintaining an
LPV/r-based regimen. Moreover, findings regarding in-
creases in visceral fat in those patients switched to ATV/r
deserve further study.
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